Reports
Reports
Sale
The global recombinant protein market was valued at USD 1.9 billion in 2023, driven by the increasing demand for effective drugs to treat chronic diseases across the globe. The market is expected to grow at a CAGR of 11.21% during the forecast period of 2024 and 2032, likely to attain a value of USD 5 billion by 2032.
Recombinant Protein Market Size
Recombinant Protein Market Growth
Recombinant Protein Market Trends
Recombinant Protein Market Share
Recombinant Protein Regional Analysis
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Recombinant Protein Market Overview
3.1 Global Recombinant Protein Market Historical Value (2017-2023)
3.2 Global Recombinant Protein Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Recombinant Protein Market Landscape*
5.1 Global Recombinant Protein: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Recombinant Protein: Product Landscape
5.2.1 Analysis by Product
5.2.2 Analysis by Vector
5.2.3 Analysis Application
5.2.4 Analysis by Cell type
6 Global Recombinant Protein Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Recombinant Protein Market Segmentation (2017-2032)
7.1 Global Recombinant Protein Market (2017-2032) by Product Type
7.1.1 Market Overview
7.1.2 Growth Factor and Cytokines
7.1.3 Hormone
7.1.4 Enzyme
7.1.5 Antibody
7.1.6 Immune Checkpoint Proteins
7.1.7 Recombinant Regulatory Proteins
7.1.8 Others
7.2 Global Recombinant Protein Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Therapeutic
7.2.3 Research
7.2.4 Biotechnology Industry
7.3 Global Recombinant Protein Market (2017-2032) by Region
7.3.1 Market Overview
7.3.2 North America
7.3.3 Europe
7.3.4 Asia Pacific
7.3.5 Latin America
7.3.6 Middle East and Africa
8 North America Recombinant Protein Market (2017-2032)
8.1 North America Recombinant Protein Market (2017-2032) by Product Type
8.1.1 Market Overview
8.1.2 Growth Factor and Cytokines
8.1.3 Hormone
8.1.4 Enzyme
8.1.5 Antibody
8.1.6 Immune Checkpoint Proteins
8.1.7 Recombinant Regulatory Proteins
8.1.8 Others
8.2 North America Recombinant Protein Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Therapeutic
8.2.3 Research
8.2.4 Biotechnology Industry
8.3 North America Recombinant Protein Market (2017-2032) by Country
8.3.1 United States of America
8.3.2 Canada
9 Europe Recombinant Protein Market (2017-2032)
9.1 Europe Recombinant Protein Market (2017-2032) by Product Type
9.1.1 Market Overview
9.1.2 Growth Factor and Cytokines
9.1.3 Hormone
9.1.4 Enzyme
9.1.5 Antibody
9.1.6 Immune Checkpoint Proteins
9.1.7 Recombinant Regulatory Proteins
9.1.8 Others
9.2 Europe Recombinant Protein Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Therapeutic
9.2.3 Research
9.2.4 Biotechnology Industry
9.3 Europe Recombinant Protein Market (2017-2032) by Country
9.3.1 United Kingdom
9.3.2 Germany
9.3.3 France
9.3.4 Italy
9.3.5 Others
10 Asia Pacific Recombinant Protein Market (2017-2032)
10.1 Asia Pacific Recombinant Protein Market (2017-2032) by Product Type
10.1.1 Market Overview
10.1.2 Growth Factor and Cytokines
10.1.3 Hormone
10.1.4 Enzyme
10.1.5 Antibody
10.1.6 Immune Checkpoint Proteins
10.1.7 Recombinant Regulatory Proteins
10.1.8 Others
10.2 Asia Pacific Recombinant Protein Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Therapeutic
10.2.3 Research
10.2.4 Biotechnology Industry
10.3 Asia Pacific Recombinant Protein Market (2017-2032) by Country
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 ASEAN
10.3.5 Australia
10.3.6 Others
11 Latin America Recombinant Protein Market (2017-2032)
11.1 Latin America Recombinant Protein Market (2017-2032) by Product Type
11.1.1 Market Overview
11.1.2 Growth Factor and Cytokines
11.1.3 Hormone
11.1.4 Enzyme
11.1.5 Antibody
11.1.6 Immune Checkpoint Proteins
11.1.7 Recombinant Regulatory Proteins
11.1.8 Others
11.2 Latin America Recombinant Protein Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Therapeutic
11.2.3 Research
11.2.4 Biotechnology Industry
11.3 Latin America Recombinant Protein Market (2017-2032) by Country
11.3.1 Brazil
11.3.2 Argentina
11.3.3 Mexico
11.3.4 Others
12 Middle East and Africa Recombinant Protein Market (2017-2032)
12.1 Middle East and Africa Recombinant Protein Market (2017-2032) by Product Type
12.1.1 Market Overview
12.1.2 Growth Factor and Cytokines
12.1.3 Hormone
12.1.4 Enzyme
12.1.5 Antibody
12.1.6 Immune Checkpoint Proteins
12.1.7 Recombinant Regulatory Proteins
12.1.8 Others
12.2 Middle East and Africa Recombinant Protein Market (2017-2032) by Application
12.2.1 Market Overview
12.2.2 Therapeutic
12.2.3 Research
12.2.4 Biotechnology Industry
12.3 Middle East and Africa Recombinant Protein Market (2017-2032) by Country
12.3.1 Saudi Arabia
12.3.2 United Arab Emirates
12.3.3 Nigeria
12.3.4 South Africa
12.3.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication Year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Clinical Trial Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Grant Analysis
16.1 Analysis by Year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Product
16.5 Analysis by Funding Institute
16.6 Analysis by Departments
16.7 Analysis by Recipient Organization
17 Funding and Investment Analysis
17.1 Analysis by Funding Instances
17.2 Analysis by Type of Funding
17.3 Analysis by Funding Amount
17.4 Analysis by Leading Players
17.5 Analysis by Leading Investors
17.6 Analysis by Geography
18 Strategic Initiative
18.1 Analysis by Partnership Instances
18.2 Analysis by Type of Partnership
18.3 Analysis by Leading Players
18.4 Analysis by Geography
19 Supplier Landscape
19.1 Market Share Analysis, By Region (Top 5 Companies)
19.1.1 Market Share Analysis: Global
19.1.2 Market Share Analysis: North America
19.1.3 Market Share Analysis: Europe
19.1.4 Market Share Analysis: Asia-Pacific
19.1.5 Market Share Analysis: Others
19.2 Abbott
19.2.1 Financial Analysis
19.2.2 Product Portfolio
19.2.3 Demographic Reach and Achievements
19.2.4 Mergers and Acquisitions
19.2.5 Certifications
19.3 Abcam PLC
19.3.1 Financial Analysis
19.3.2 Product Portfolio
19.3.3 Demographic Reach and Achievements
19.3.4 Mergers and Acquisitions
19.3.5 Certifications
19.4 Thermo Fisher Scientific, Inc .
19.4.1 Financial Analysis
19.4.2 Product Portfolio
19.4.3 Demographic Reach and Achievements
19.4.4 Mergers and Acquisitions
19.4.5 Certifications
19.5 Bio-Techne Corp .
19.5.1 Financial Analysis
19.5.2 Product Portfolio
19.5.3 Demographic Reach and Achievements
19.5.4 Mergers and Acquisitions
19.5.5 Certifications
19.6 Merck KGaA
19.6.1 Financial Analysis
19.6.2 Product Portfolio
19.6.3 Demographic Reach and Achievements
19.6.4 Mergers and Acquisitions
19.6.5 Certifications
19.7 Bio-Rad Laboratories, Inc .
19.7.1 Financial Analysis
19.7.2 Product Portfolio
19.7.3 Demographic Reach and Achievements
19.7.4 Mergers and Acquisitions
19.7.5 Certifications
19.8 GeneTex, Inc
19.8.1 Financial Analysis
19.8.2 Product Portfolio
19.8.3 Demographic Reach and Achievements
19.8.4 Mergers and Acquisitions
19.8.5 Certifications
19.9 Lonza Group SA
19.9.1 Financial Analysis
19.9.2 Product Portfolio
19.9.3 Demographic Reach and Achievements
19.9.4 Mergers and Acquisitions
19.9.5 Certifications
19.10 F. Hoffmann-La Roche Ltd .
19.10.1 Financial Analysis
19.10.2 Product Portfolio
19.10.3 Demographic Reach and Achievements
19.10.4 Mergers and Acquisitions
19.10.5 Certifications
19.11 PerkinElmer Inc .
19.11.1 Financial Analysis
19.11.2 Product Portfolio
19.11.3 Demographic
19.11.4 Mergers and Acquisitions
19.11.5 Certifications
19.12 Sino Biological Inc .
19.12.1 Financial Analysis
19.12.2 Product Portfolio
19.12.3 Demographic Reach and Achievements
19.12.4 Mergers and Acquisitions
19.12.5 Certifications
19.13 TAKARA HOLDINGS INC .
19.13.1 Financial Analysis
19.13.2 Product Portfolio
19.13.3 Demographic Reach and Achievements
19.13.4 Mergers and Acquisitions
19.13.5 Certifications
19.14 Tosoh Corporation
19.14.1 Financial Analysis
19.14.2 Product Portfolio
19.14.3 Demographic Reach and Achievements
19.14.4 Mergers and Acquisitions
19.14.5 Certifications
19.15 XENOTECH AI Pvt Ltd .
19.15.1 Financial Analysis
19.15.2 Product Portfolio
19.15.3 Demographic Reach and Achievements
19.15.4 Mergers and Acquisitions
19.15.5 Certifications
19.16 NEW ENGLAND BIOLABS, INC
19.16.1 Financial Analysis
19.16.2 Product Portfolio
19.16.3 Demographic Reach and Achievements
19.16.4 Mergers and Acquisitions
19.16.5 Certifications
20 Recombinant Protein Market – Distribution Model (Additional Insight)
20.1 Overview
20.2 Potential Distributors
20.3 Key Parameters for Distribution Partner Assessment
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive, moreover we can provide analysis of companies as per custom request.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.